DBV Technologies (DBVT) Plunged To A New Low After Phase 3 Study Failed

DBV Technologies (DBVT) announced late Friday that its Phase III trial of Viaskin Peanut in children four to 11 years of age failed to meet its primary endpoint.

from RTT - Before the Bell http://ift.tt/2yL2HhH
via IFTTT